Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

Thank You Digital RESI June Sponsors

3 Jun

By Elizabeth Murphy, Manager of Business Development, LSN

Life Science Nation (LSN) is pleased to feature its stellar lineup of Digital RESI June sponsors, including our inaugural Service Provider Showcase. Digital RESI June takes place next week, June 8-10, and features a vibrant agenda punctuated by active sponsors seeking to add value to the RESI community in their early-stage fundraising and beyond!

Check out each sponsor below and visit our workshops page to learn more about sponsors on the agenda. Each company will be participating within the partnering platform and available to message and book meetings with, so sign up before it’s too late.

Title Sponsors
Gold Sponsor Silver Sponsor
Service Provider Showcase
Media Partners

Last Chance to Sign Up for Digital RESI June

3 Jun

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital Redefining Early Stage Investments (RESI), June 8-10 is just around the corner, but there’s still time to sign up and meet with 400+ investors. Partnering is open and RESI’s premier partnering platform is designed to help investors, entrepreneurs, and service providers target leads and book meetings with those who are a fit for their needs.

Learn more about the RESI partnering system and see who will be there. Don’t miss your chance to jumpstart a fundraise with strategic partners who are a fit for you! Register today – We hope to see you next week!

Confirmed Digital RESI June Investors and Strategic Partners*

*June 3, 2021

Digital RESI June Innovator’s Pitch Challenge Finalists

27 May

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


With the next Digital Redefining Early Stage Investments (RESI) conference taking place in less than two weeks, Life Science Nation (LSN) is pleased to announce the fifty companies presenting in the Digital RESI June’s Innovator’s Pitch Challenge (IPC).

The IPC’s unique format and approach to connecting startups to investors has made it a popular feature at Digital RESI, and the team has received a record number of applications from startups across the globe. These sessions are not only helpful for companies trying to increase their exposure in the life sciences community, but also for investors who are actively looking at early-stage innovations. Many have found IPC sessions a fun and productive way to engage with one another.

The ten sessions are divided based on sector and types of technologies, with each session featuring five companies and a panel of investor judges for live engagement and a Q&A segment. If you’re interested in seeing a live pitch session and connecting with investors who are a fit for your product and stage of development, there’s still time to register for Digital RESI June. Select a logo to learn more about each finalist company:

Innovator’s Pitch Challenge #1 (Oncology)
Tuesday, June 8, 11:00AM – 12:00PM EDT


Innovator’s Pitch Challenge #2 (Medical Devices)
Tuesday, June 8, 1:00PM – 2:00PM EDT


Innovator’s Pitch Challenge #3 (Digital Health)
Tuesday, June 8, 3:00PM – 4:00PM EDT


Innovator’s Pitch Challenge #4 (Diagnostics)
Tuesday, June 8, 5:00PM – 6:00PM EDT


Innovator’s Pitch Challenge #5 (Therapeutics)
Wednesday, June 9, 12:00PM – 1:00PM EDT


Innovator’s Pitch Challenge #6 (Novel Drug Delivery)
Wednesday, June 9, 3:00PM – 4:00PM EDT


Innovator’s Pitch Challenge #7 (Medical Devices & Diagnostics)
Wednesday, June 9 5:00PM – 6:00PM EDT


Innovator’s Pitch Challenge #8 (Therapeutics & Diagnostics)
Thursday, June 10, 12:00PM – 1:00PM EDT


Innovator’s Pitch Challenge #9 (Advanced Therapies)
Thursday, June 10, 3:00PM – 4:00PM EDT


Innovator’s Pitch Challenge #10 (Therapeutics)
Thursday, June 10, 4:00PM – 5:00PM EDT

How to Optimize and Expedite Regulatory Approval with Amarex

27 May

By Elizabeth Murphy, Manager of Business Development, LSN

Amarex Clinical Research is part of the Digital Redefining Early Stage Investments (RESI) June Service Provider Showcase, and will be hosting a live workshop on Tuesday, June 8 at 12:30 PM EDT. Join President and CEO, Dr. Kazem Kazempour for the workshop, Approaches to Expediting U.S. FDA Submissions/Trial Initiations & Acceptance of Foreign Data by the U.S. FDA. Register for RESI June today and sign up to join this workshop and take advantage of Digital RESI June’s lineup of insightful investor panels and the premier match-based partnering system

Approaches to Expediting U.S. FDA Submissions/Trial Initiations & Acceptance of Foreign Data by the U.S. FDA

Dr. Kazem Kazempour, President & CEO, Amarex Clinical Research, LLC

Sponsors who submit investigational new drug (IND) or investigational device exemption (IDE) applications to the U.S. FDA receive many benefits for their clinical products. These include fast turn-around time from submission to trial approval, the ability to submit in parallel to regulatory agencies outside of the U.S., guidance from the FDA at no cost, access to accelerated approval pathways when applicable, and preparation for approval in other countries. Taking advantage of all available FDA approval pathways is a key factor in successfully expediting clinical product development. Once the FDA deems an IND/IDE as safe to proceed, effective clinical trial strategies that take advantage of all regulatory pathways are paramount to reducing time to market approval. Adaptive trial designs and parallel processes are major components to consider at the trial design and conduct stages. Non-U.S. generated clinical data is accepted by the U.S. FDA, but with provisions, and allows for starting trials in the U.S. at a later stage in the process. Acceptance criteria exist to help sponsors use clinical data from outside the U.S. and knowledge of practical issues, e.g., regulatory, logistical, scientific, and administrative, are essential.

A Match Made at RESI: Part II

27 May

By Rory McCann, Marketing Manager & Conference Producer, LSN

Antoine Prestat and Michele Marzola met at Digital RESI March and spent the past several months building up a strategic partnership that will help launch French biotech, PEP-Therapy into clinical trials this summer.

In Part II of our two-part interview about Michele and Antoine’s strategic partnership, we discuss how PEP-Therapy stood out at RESI, and how Antoine worked with investors for a strong Series A raise.

Check out Part I of our interview and if you’re looking to get in front of qualified investors at Digital RESI June, there’s still time to sign up!

Join These Investor Panelists at Digital RESI June

20 May

By Joey Wong, Investor Research Analyst, LSN

Digital Redefining Early Stage Investment (RESI) Conference, June 8-10, takes place in just a few weeks! The Life Science Nation (LSN) investor research team has been busy organizing six exciting panels focusing on different investor groups, from big pharma, corporate venture capital, to family offices and angel investors, etc. During these panels, active life science investors will share their insight and provide tactical advice on outreach, positioning, and building the right relationships to move products forward. The goal is to facilitate constructive conversations between investors and fundraising CEOs, and provide insights on how companies can raise capital and acquire partnerships effectively.

Another exciting part of the upcoming conference is the Innovator’s Pitch Challenge, where investors and industry experts are invited to participate in the live Q&A sessions to give feedback and ask questions to the pitching companies.

If you are interested in meeting these investor panelists and pitch judges, register here for Digital RESI June! Partnering is open, but there is still time to sign up!

For those who have already registered, we highly recommend you to join the panels that are relevant to your company; you can RSVP for any panels in the partnering system to block off your meeting schedule.

Here are some of the investors who will be joining our panels and pitch sessions at Digital RESI June:

Hamzeh Abdul-Hadi
Hikma Ventures
Brent Ahrens
General Partner
Canaan Partners
Faz Bashi
Member of BOD
Life Science Angels
Attila Bérces
Brian Bronk
Head of External Innovation, Rare Diseases
Hannah Chang
Managing Director
Wu Capital
Elizabeth Cho-Fertikh
Co-Founder & Managing Director
Meda Angels
Chris Church
Associate Director, Search & Evaluation, CVRM
Juan Cueva
Senior Associate
Action Potential Venture Capital
Geoff Dacosta
Director, Business Development and Licensing
Ben Evans
Managing Director
InHealth Ventures
Naomi Fried
Managing Director & Co-Founder
Ambit Health Ventures
Robert Garber
7wire Ventures
Miles Gerson
Takeda Ventures
Sam Goldberger
Co-Founder & Managing Partner
Ambit Health Ventures
Sherry Grisewood
Senior Investment Officer
FoxHill Asset Management
Bryan Grulke
Volcano Capital
Eric Heinz
Director, Business Development (M&A)
Smith & Nephew
Merom Klein
Entrepreneur Mentor
Keiretsu Forum
Marc Martin-Casas
Seed Investments & Development
Illumina Accelerator
Andy Merken
Partner, Corporate and Securities Co-Chair, Life Sciences
Burns & Levinson
Brian Meshkin
Managing Partner, Profound Ventures Partner, Cancer Fund
Profound Ventures
Petra Meyer
Managing Director – HealthCare Sector Group Lead
Golden Seeds
Junaid Mian
Managing Partner & Longevity Lead
Nicholas Mourlas
Senior Director, New Ventures
Johnson & Johnson Innovation
Ashley Ng
McKesson Ventures
John Parker
Founder & Managing Director
Springhood Ventures
Richard Proscia
Senior Associate
Providence Ventures
Meghana Rao
Senior Manager, New Venture Transactions
Johnson & Johnson Innovation
Nadav Shimoni
Head, Digital Health
Arkin Holdings Ltd
Yaniv Sneor
Founding Member
Mid Atlantic Bio Angels
Jill Sorensen
Chief Operating Officer
Medical Technology Enterprise Consortium (MTEC)
Eran Steinberg


Imaging Arts

Ben Sun
Sand Hill Angels
Anna Turetsky
Principal, Venture Investments
The Mark Foundation for Cancer Research (MFCR)
Thomas Vogelsong
Investor/Life Science Advisor
KYTO Technology and Life Science
Scott Weiner
Amzak Health
Tim Xiao
Delos Capital
John Yianni
Managing Partner

Introducing RESI AI Panels

20 May

By Caitlin Dolegowski, Marketing Specialist, LSN


Life Science Nation has released panel topics for its upcoming digital partnering conference: RESI AI, September 16-17. RESI AI panels host active investors who are joined by founders of portfolio companies to discuss funding, the early-stage landscape for AI companies in healthcare, and what makes a successful strategic partnership. Register by July 23 to save on super early bird rates.

There are many exciting advancements in this dynamic sector of life sciences, and we hope you’ll join us in highlighting the latest innovations, as well as take advantage of the powerful partnering system that has made RESI events a mainstay in early-stage fundraising.

If you’d like to be considered to join a RESI AI panel, please apply here.

The RESI AI panels will focus on the following topics:

Healthcare Communications

Bridging the Gaps between Patient and Provider

Communication between patients and providers is essential to health systems globally. AI-enabled technology addressing these needs and creating innovative solutions help patients better access and comprehend their options and care. Hear from early-stage founders connecting the healthcare system one relationship at a time.

Accelerated Pharmaceutical Development

Advancing and Optimizing Clinical Processes

AI is a necessary component of many aspects of the development of pharmaceuticals. However, the COVID-19 global pandemic has highlighted the need for rapid and reliable pharmaceutical advancement. Learn how researchers can utilize AI to optimize performance and save lives.

Reproductive Wellness

Highlighting Innovation and Broad Applications

Comprehensive reproductive care has a global impact on health and society. AI-assisted advancement in this field is critical to provide access to patients regardless of location, medical history, and socioeconomic status. Hear from leaders how their technology is creating equity in quality and excellence in care.

Diagnostic Wearables

Connecting Patients to Their Health

Wearable sensors are a fast-growing area of medical device and diagnostic technology. The function and accuracy of these devices are critical to patient care and communication. AI is a powerful tool equipping these to provide accurate results up to the moment and enabling users to make well-informed decisions on their health.

Healthcare Systems and Infrastructure

Creating Synergy for Efficient Patient Care

Optimized healthcare systems and digital infrastructure are paramount to the patient experience. From electronic health records to portal access and communications, AI-enabled medical centers are better equipped to help patients in the digital age. When it comes to healthcare, small synergistic changes create a big impact on the patient experience and contribute to better systems globally.

Precision Medicine

Fitting the AI Piece of the Puzzle

The AI impact on precision medicine is essential in targeting and treating genetic disorders, rare diseases, oncology, and more. It’s important that entrepreneurs learn how to navigate pitfalls such as market saturation, regulatory risk and guidelines, as well as how to better define patient populations, challenges and tackle manufacturing and commercialization.

%d bloggers like this: